EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Protection of Adipose Tissue by Pioglitazone in a Mouse Model of Doxorubicin Treatment

Loreana Sanches Silveira, Alexandre Abilio de Souza Teixeira iD, Luana Amorim Biondo, Luísa Menezes Silva, Luís Eduardo Duarte Gonçalves, Ana Beatriz Lima Pedroza, Niels Olsen Saraiva Camara iD, José Cesar Rosa-Neto

Cell Biochemistry and Function · 2025

DOI: 10.1002/cbf.70120 ↗

At a glance

Journal article in Cell Biochemistry and Function, 2025. Written by Loreana Sanches Silveira and 7 co-authors. Institution: Immunometabolism Research Group, Department of Cell Biology and Development, Institute of Biomedical Sciences, University of São Paulo (ICB1-USP), Sã…. Major MEDLINE topics: Pioglitazone, Doxorubicin, Adipose Tissue, White, Adipose Tissue. 45 references. The full text is freely available (open access, CC BY 4.0). Funded by: This study was supported by CNPQ; FAPESP, grant nos. 2019/09854-9, 2019/09679-2, 2021/00352-0, 2022/06073-9..

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Cancer is a global epidemic with increasing incidence, which needs continuous efforts to enhance treatment efficacy and reduce side effects. Our study focuses on the impact of doxorubicin, a widely used chemotherapeutic agent, on white adipose tissue (WAT) homeostasis and explores the potential mitigating effects of coadministration with pioglitazone, a peroxisome proliferator‐activated receptor‐gamma (PPARγ) activator. Using male C57BL/6 mice, we investigated the influence of doxorubicin and pioglitazone on WAT, considering factors such as weight loss, metabolic parameters, lipolysis, adipokines, and immune cell infiltration. Doxorubicin treatment resulted in weight loss, specifically affecting visceral adipose tissue, while coadministration with pioglitazone preserved inguinal adipose tissue (iWAT). Metabolic analyses revealed that doxorubicin induced hypoglycaemia, mitigated by pioglitazone, without significant effects on lipid profiles. Pioglitazone ameliorated the doxorubicin‐induced reduction in adiponectin, thereby contributing to the maintenance of glucose homeostasis. Lipolysis assays demonstrated doxorubicin‐induced lipotoxicity, particularly in (iWAT), which was attenuated by pioglitazone. Histological analysis showed no significant changes in adipocyte size, while flow cytometry revealed a reduction in pro‐inflammatory M1 macrophages in the co‐treated group. Based on gene expression profiles, pioglitazone appeared to modulate genes involved in lipid metabolism, with preliminary indications of a potential role in adipogenic processes. In summary, coadministration of pioglitazone during doxorubicin treatment appeared to attenuate alterations in WAT homeostasis associated with lipotoxicity. These findings contribute to the understanding of potential supportive strategies during doxorubicin‐based chemotherapy. Further studies should be conducted to define appropriate dosing regimens, treatment durations, and to evaluate potential effects on cancer progression and patient outcomes.

Subjects

MeSH terms (MEDLINE)

PioglitazoneDoxorubicinAdipose Tissue, WhiteAdipose TissueAnimalsMaleMiceMice, Inbred C57BLDisease Models, AnimalLipolysisLipid Metabolism

Author keywords

PPAR gammadoxorubicinlipid metabolismrosiglitazonethiazolidinediones

Substances

PioglitazoneDoxorubicin

Authors and institutions

  • Immunometabolism Research Group, Department of Cell Biology and Development, Institute of Biomedical Sciences, University of São Paulo (ICB1-USP), São Paulo, Brazil.
  • Department of Immunology, Institute of Biomedical Sciences, University of São Paulo (ICB4-USP), São Paulo, Brazil.

ORCID profiles: Alexandre Abilio de Souza Teixeira, Niels Olsen Saraiva Camara

Funding

  • This study was supported by CNPQ; FAPESP, grant nos. 2019/09854-9, 2019/09679-2, 2021/00352-0, 2022/06073-9.

Cite

APA

Silveira, L. S., de Souza Teixeira, A. A., Biondo, L. A., Silva, L. M., Gonçalves, L. E. D., Pedroza, A. B. L., Camara, N. O. S., & Rosa-Neto, J. C. (2025). Protection of Adipose Tissue by Pioglitazone in a Mouse Model of Doxorubicin Treatment. Cell Biochemistry and Function. https://doi.org/10.1002/cbf.70120

Vancouver

Silveira LS, de Souza Teixeira AA, Biondo LA, Silva LM, Gonçalves LED, Pedroza ABL, et al. Protection of Adipose Tissue by Pioglitazone in a Mouse Model of Doxorubicin Treatment. Cell Biochemistry and Function. 2025. doi:10.1002/cbf.70120

BibTeX
@article{Silveira2025,
  author = {Silveira, Loreana Sanches and de Souza Teixeira, Alexandre Abilio and Biondo, Luana Amorim and Silva, Luísa Menezes and Gonçalves, Luís Eduardo Duarte and Pedroza, Ana Beatriz Lima and Camara, Niels Olsen Saraiva and Rosa-Neto, José Cesar},
  title = {Protection of Adipose Tissue by Pioglitazone in a Mouse Model of Doxorubicin Treatment},
  journal = {Cell Biochemistry and Function},
  year = {2025},
  doi = {10.1002/cbf.70120}
}
Start for free →